The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1515
Kyleena - Another Hormonal IUD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Kyleena (Bayer), an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy. It is the fourth levonorgestrel-releasing IUD to be approved in the US. Like Mirena, which has been available since 2000, Kyleena is approved for up to 5 years of use.

IUDs — IUDs provide convenient, long-term contraception and a rapid return to fertility after removal; they are considered safe for use in most women, including adolescents and nulliparous women.1 All levonorgestrel-releasing IUDs, which are approved for 3 or 5 years of use, can reduce menstrual bleeding and dysmenorrhea. Amenorrhea can occur, especially with devices that contain more levonorgestrel.2 ParaGard T380A, a copper-containing IUD, is FDA-approved for up to 10 years ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Kyleena - Another Hormonal IUD
Article code: 1515e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian